Yang et al., 2009 - Google Patents
Synthesis, self-assembly, and in vitro doxorubicin release behavior of dendron-like/linear/dendron-like poly (ε-caprolactone)-b-poly (ethylene glycol)-b-poly (ε …Yang et al., 2009
- Document ID
- 4375395005102907820
- Author
- Yang Y
- Hua C
- Dong C
- Publication year
- Publication venue
- Biomacromolecules
External Links
Snippet
Dendron-like/linear/dendron-like poly (ε-caprolactone)-b-poly (ethylene glycol)-b-poly (ε- caprolactone) triblock copolymers with controlled molecular weights (M n= 9550− 30 460) and low polydispersities were synthesized by a click conjugation between dendron-like poly …
- 229920001577 copolymer 0 title abstract description 112
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48876—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core
- A61K47/48884—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/48892—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/489—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the material constituting the nanoparticle being a polymer obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone, polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48169—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule
- A61K47/48192—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being an organic macromolecular compound, i.e. an oligomeric, polymeric, dendrimeric molecule the organic macromolecular compound has been obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas, polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, copolymers of polyalkylene glycol or poloxamer
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Synthesis, self-assembly, and in vitro doxorubicin release behavior of dendron-like/linear/dendron-like poly (ε-caprolactone)-b-poly (ethylene glycol)-b-poly (ε-caprolactone) triblock copolymers | |
| Deirram et al. | pH‐responsive polymer nanoparticles for drug delivery | |
| Johnson et al. | Core-clickable PEG-branch-azide bivalent-bottle-brush polymers by ROMP: grafting-through and clicking-to | |
| Baranello et al. | Poly (styrene-alt-maleic anhydride)-based diblock copolymer micelles exhibit versatile hydrophobic drug loading, drug-dependent release, and internalization by multidrug resistant ovarian cancer cells | |
| Hua et al. | Synthesis and characterization of linear-dendron-like poly (ε-caprolactone)-b-poly (ethylene oxide) copolymers via the combination of ring-opening polymerization and click chemistry | |
| Sun et al. | NIR-responsive and lectin-binding doxorubicin-loaded nanomedicine from Janus-type dendritic PAMAM amphiphiles | |
| Yu et al. | Functional polylactide-g-paclitaxel–poly (ethylene glycol) by azide–alkyne click chemistry | |
| Chan et al. | Acid-labile core cross-linked micelles for pH-triggered release of antitumor drugs | |
| Huynh et al. | Acid degradable cross-linked micelles for the delivery of cisplatin: a comparison with nondegradable cross-linker | |
| Zhang et al. | Redox-responsive, core cross-linked polyester micelles | |
| Yang et al. | Synthesis and physicochemical characterization of amphiphilic triblock copolymer brush containing pH-sensitive linkage for oral drug delivery | |
| Soliman et al. | Dendrimers and miktoarm polymers based multivalent nanocarriers for efficient and targeted drug delivery | |
| Chen et al. | Photo-cross-linked and pH-sensitive biodegradable micelles for doxorubicin delivery | |
| Duong et al. | Acid degradable and biocompatible polymeric nanoparticles for the potential codelivery of therapeutic agents | |
| Fuoco et al. | Redox-responsive disulfide cross-linked PLA–PEG nanoparticles | |
| Bensaid et al. | Y-shaped mPEG-PLA cabazitaxel conjugates: well-controlled synthesis by organocatalytic approach and self-assembly into interface drug-loaded core–corona nanoparticles | |
| Chang et al. | Synthesis of hyperbranched polypeptide and PEO block copolymer by consecutive thiol-yne chemistry | |
| Gao et al. | Aminated linear and star-shape poly (glycerol methacrylate) s: synthesis and self-assembling properties | |
| Yang et al. | Acid-labile poly (glycidyl methacrylate)-based star gene vectors | |
| El Jundi et al. | Double-hydrophilic block copolymers based on functional poly (ε-caprolactone) s for pH-dependent controlled drug delivery | |
| Zhao et al. | Tumor acidity-induced sheddable polyethylenimine-poly (trimethylene carbonate)/DNA/polyethylene glycol-2, 3-dimethylmaleicanhydride ternary complex for efficient and safe gene delivery | |
| Holm et al. | Impact of branching on the solution behavior and serum stability of starlike block copolymers | |
| Wang et al. | Optimization of amphiphilic miktoarm star copolymers for anticancer drug delivery | |
| Liu et al. | Versatile strategy for the synthesis of hyperbranched poly (ε-caprolactone) s and polypseudorotaxanes thereof | |
| Legros et al. | Poly (2-oxazoline)-based nanogels as biocompatible pseudopolypeptide nanoparticles |